These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492 [TBL] [Abstract][Full Text] [Related]
24. Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Della Chiesa M; Romagnani C; Thiel A; Moretta L; Moretta A Blood; 2006 Dec; 108(12):3851-8. PubMed ID: 16873676 [TBL] [Abstract][Full Text] [Related]
25. Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention. Molfetta R; Zingoni A; Santoni A; Paolini R Front Immunol; 2019; 10():2557. PubMed ID: 31736972 [TBL] [Abstract][Full Text] [Related]
26. Discovering Che-1/AATF: a new attractive target for cancer therapy. Iezzi S; Fanciulli M Front Genet; 2015; 6():141. PubMed ID: 25914721 [TBL] [Abstract][Full Text] [Related]
27. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800 [TBL] [Abstract][Full Text] [Related]
28. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766 [TBL] [Abstract][Full Text] [Related]
29. Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter. Di Padova M; Bruno T; De Nicola F; Iezzi S; D'Angelo C; Gallo R; Nicosia D; Corbi N; Biroccio A; Floridi A; Passananti C; Fanciulli M J Biol Chem; 2003 Sep; 278(38):36496-504. PubMed ID: 12847090 [TBL] [Abstract][Full Text] [Related]
30. [Nectins and nectin-like receptors DNAM-1 and CRTAM: new ways for tumor escape]. Catros V; Dessarthe B; Thedrez A; Toutirais O Med Sci (Paris); 2014 May; 30(5):537-43. PubMed ID: 24939541 [TBL] [Abstract][Full Text] [Related]
31. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029 [TBL] [Abstract][Full Text] [Related]
32. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Diefenbach A; Hsia JK; Hsiung MY; Raulet DH Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935 [TBL] [Abstract][Full Text] [Related]
33. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. Bilotta MT; Abruzzese MP; Molfetta R; Scarno G; Fionda C; Zingoni A; Soriani A; Garofalo T; Petrucci MT; Ricciardi MR; Paolini R; Santoni A; Cippitelli M FASEB J; 2019 Aug; 33(8):9489-9504. PubMed ID: 31125275 [TBL] [Abstract][Full Text] [Related]
34. Che-1/AATF binds to RNA polymerase I machinery and sustains ribosomal RNA gene transcription. Sorino C; Catena V; Bruno T; De Nicola F; Scalera S; Bossi G; Fabretti F; Mano M; De Smaele E; Fanciulli M; Iezzi S Nucleic Acids Res; 2020 Jun; 48(11):5891-5906. PubMed ID: 32421830 [TBL] [Abstract][Full Text] [Related]
35. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383 [TBL] [Abstract][Full Text] [Related]
36. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells Focaccetti C; Benvenuto M; Pighi C; Vitelli A; Napolitano F; Cotugno N; Fruci D; Palma P; Rossi P; Bei R; Cifaldi L Front Immunol; 2022; 13():886319. PubMed ID: 35967339 [TBL] [Abstract][Full Text] [Related]
37. Identification of neuroblastoma cell lines with uncommon TAZ Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207 [TBL] [Abstract][Full Text] [Related]
38. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960 [TBL] [Abstract][Full Text] [Related]
39. The MHC class I molecule H-2Dp inhibits murine NK cells via the inhibitory receptor Ly49A. Olsson-Alheim MY; Sundbäck J; Kärre K; Sentman CL J Immunol; 1999 Jun; 162(12):7010-4. PubMed ID: 10358142 [TBL] [Abstract][Full Text] [Related]
40. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Moretta A; Bottino C; Vitale M; Pende D; Cantoni C; Mingari MC; Biassoni R; Moretta L Annu Rev Immunol; 2001; 19():197-223. PubMed ID: 11244035 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]